Intra-tumoral delivery of 5ʹppp-dsRNA induces a robust antitumor response via RIG-I activation and Bcl-2 gene downregulation in a murine model of prostate cancer
International Immunology · 2024
DOI: 10.1093/intimm/dxae061 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunology, 2024. Verfasst von Kasturi Ganguly und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Innate Immunity, Indian Council of Medical Research (ICMR)-National Institute for Research in Reproductive and Child Health, Mumbai, In…. Hauptthemen laut MEDLINE: DEAD Box Protein 58, Prostatic Neoplasms, Down-Regulation, Proto-Oncogene Proteins c-bcl-2. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 65 Literaturangaben. Gefördert von: ICMR-NIRRCH, Council of Scientific and Industrial Research (CSIR).
Abstract (Originalsprache)
Onco-immunotherapy via blocking checkpoint inhibitors has revolutionized the treatment-landscape of several malignancies, though not in the metastatic castration-resistant prostate cancer (PCa) owing to an immunosuppressive and poorly immunogenic “cold” tumor microenvironment (TME). Turning up the heat of such a cold TME via triggering innate immunity is now of increasing interest to restore immune-surveillance. Retinoic acid-inducible gene-I (RIG-I)-like receptors (RLRs) are cytosolic innate-sensors that can detect exogenous RNAs and induce type-I interferons and other pro-inflammatory signaling. RIG-I activation is suggested to be a valuable addition to the treatment approaches for several cancers. However, the knowledge about RIG-I signaling in PCa remains elusive. The present study evaluated the expression of two important RLRs, RIG-I and melanoma differentiation-associated protein 5 (MDA5), along with their downstream partners, mitochondrial antiviral-signaling protein (MAVS) and ERA G-protein-like 1 (ERAL1), during PCa progression in the transgenic adenocarcinoma of mouse prostate (TRAMP) model. The early stage of PCa revealed a significant increment in the expression of RLRs but not MAVS. However, the advanced stage showed downregulated RLR signaling. Further, the therapeutic implication of 5ʹppp-dsRNA, a synthetic RIG-I agonist and Bcl2 gene silencer, has been investigated in vitro and in vivo. Intra-tumoral delivery of 5ʹppp-dsRNA regressed tumor growth via triggering tumor cell apoptosis, immunomodulation, and inducing phagocytic “eat me” signals. These findings highlight that, for the first time, RIG-I activation and Bcl-2 silencing with 5ʹppp-dsRNA can serve as a potent tumor-suppressor strategy in PCa and has a significant clinical implication in transforming a “cold” TME into an immunogenic “hot” TME of PCa.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Innate Immunity, Indian Council of Medical Research (ICMR)-National Institute for Research in Reproductive and Child Health, Mumbai, India.
- Experimental Animal Facility, Indian Council of Medical Research (ICMR)-National Institute for Research in Reproductive and Child Health, Mumbai, India.
- Division of Development Research, Indian Council of Medical Research (ICMR), New Delhi, India.
Förderung
- ICMR-NIRRCH
- Council of Scientific and Industrial Research (CSIR)
Zitieren
APA
Ganguly, K., Metkari, S. M., Biswas, B., Subedi, R., & Madan, T. (2024). Intra-tumoral delivery of 5ʹppp-dsRNA induces a robust antitumor response via RIG-I activation and Bcl-2 gene downregulation in a murine model of prostate cancer. International Immunology. https://doi.org/10.1093/intimm/dxae061
Vancouver
Ganguly K, Metkari SM, Biswas B, Subedi R, Madan T. Intra-tumoral delivery of 5ʹppp-dsRNA induces a robust antitumor response via RIG-I activation and Bcl-2 gene downregulation in a murine model of prostate cancer. International Immunology. 2024. doi:10.1093/intimm/dxae061
BibTeX
@article{Ganguly2024,
author = {Ganguly, Kasturi and Metkari, Siddhanath M and Biswas, Barnali and Subedi, Rambhadur and Madan, Taruna},
title = {Intra-tumoral delivery of 5ʹppp-dsRNA induces a robust antitumor response via RIG-I activation and Bcl-2 gene downregulation in a murine model of prostate cancer},
journal = {International Immunology},
year = {2024},
doi = {10.1093/intimm/dxae061}
}
EUVIMED